We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
+19.65%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$240M
AUM Growth
+$18.4M
Cap. Flow
-$20.4M
Cap. Flow %
-8.53%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$204M 84.96%
8,984,300
-1,046,400
-10% -$20.4M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$20.7M 8.65%
4,468,835
EPI icon
3
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$7.7M 3.21%
213,800
INDA icon
4
iShares MSCI India ETF
INDA
$6.71B
$7.63M 3.18%
171,200

Similar funds

Meditor Group's Q1 2022 Portfolio in Review

As of Q1 2022, Meditor Group held 4 positions worth $240M, up 8.3% from $221M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group withdrew a net $20.4M in Q1 2022, reducing 1 holding. Its largest reduction was Exelixis, cutting an estimated $20.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

  • Meditor Group's biggest Q1 2022 reduction was Exelixis, cutting an estimated $20.4M.
  • Meditor Group's ten largest holdings make up 100% of its $240M portfolio in Q1 2022.
  • Meditor Group opened 0 new positions and closed 0 in Q1 2022.
  • Meditor Group's portfolio value rose 8.3% quarter-over-quarter to $240M.

Based on Meditor Group's 13F filing for Q1 2022, filed 12 Apr 2022.